The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: Results of a prospective randomized trial

Diabetes Care

Volumn 26, Issue 6, 2003, Pages 1701-1705

  Marston, William A ^a,f   Hanft, Jason ^b   Norwood, Paul ^c   Pollak, Richard ^d,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Foot and Ankle Institute of South Florida   (United States)

^c Valley Endocrine   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Dermagraft Joint Venture   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; FIBROBLAST; FOOT ULCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SHOE; TREATMENT OUTCOME; WOUND CLOSURE; WOUND DRESSING; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; CRYOPRESERVATION; DIABETIC FOOT; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SAFETY; SHOES; SKIN, ARTIFICIAL;

EID: 0043171152     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.6.1701     Document Type: Article

References (20)

1. Sanders LJ: Diabetes mellitus: prevention of amputation. J Am Podiatric Assoc 84:322-328, 1994
2. Levin M: Prevention and treatment of diabetic foot ulcers. J Wound Ostomy Continence Nurs 21:129-146, 1998
3. Bloomgarden ZT: American Diabetes Association 60th Scientific Sessions, 2002: the diabetic foot. Diabetes Care 24:946-951, 2001
4. Ollendorf D, Kotsanos J, Wishner W: Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 21:1240-1245, 1998
5. Loots MA, Lamme EN, Mekkes J, Middlekoop E: Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 111:850-857, 1998
6. Lazarus G, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC: Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 130:489-493, 1994
7. Hehenberger K, Heilborn K, Brismar K, Hansson A: Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L-lactate. Wound Rep Regen 6:135-141, 1998
8. Falanga VF, Grinnel B, Gilchrist Y, Maddox T, Moshelle A: Experimental approaches to chronic wounds. Wound Rep Reg 3:132-140, 1995
9. Naughton G, Mansbridge J, Gentzkow G: A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs 21:1203-1210, 1997
10. Reiber GE, Boyko EJ, Smith DG: Lower extremity foot ulcers and amputations in diabetics. In Diabetes in America. 2nd ed. Harris MI, Cowie C, Stern MP, Eds. NIH Publications No. 95, 1995, p. 1468
11. Gentzkow GD, Jensen JL, Pollak RA, Kroeker RA, Lerner JM, Iwasaki SD: Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. Wounds 11:77-84, 1999
12. Hanft JR, Surprenant MS: Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 41:291-299, 2002
13. Steed DL, and the Diabetic Foot Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic foot ulcers. J Vasc Surg 21:71-81, 1995
14. Veves A, Falanga V, Armstrong D, Sabolinski M, for the Diabetic Foot Ulcer Group: Graftskin, a human skin equivalent, is effective in the management of non-infected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24:290-295, 2001
15. Pinney E, Liu K, Sheeman B, Mansbndge J: Human three-dimensional fibroblasts cultures express angiogenic activity. J Cell Physiol 183:74-82, 2000
16. Harding KG, Brassard A, Dolynchuck K: Treatment of "hard to heal" venous leg ulcers with a human dermal replacement tissue (Dermagraft): a clinical, laboratory evaluation (Abstract). First World Wound Healing Congress, Melbourne, Australia, 2000
17. Krejci-Papa NC, Hoang A, Hansbrough JF: Fibroblast sheets enable epithelialization of wounds that do not support keratinocyle migration. Tissue Engin 5:555-561, 1999
18. Kern A, Liu K, Mansbridge J: Modification of fibroblast interferon-gamma response by dermal fibroblast extracellular matrix. Ann N Y Acad Sci 961:364-367, 2002
19. Browne AC, Vearncombe M, Sibbald RG: High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft. Ostomy Wound Manage 47:44-49, 2001
20. Falanga V: Classifications for wound bed preparation and stimulation of chronic wounds. Wound Rep Regen 8:347-352, 2000